Edmonton protocol: Difference between revisions
CSV import |
No edit summary Tag: Manual revert |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 29: | Line 29: | ||
{{stub}} | {{stub}} | ||
{{No image}} | |||
Latest revision as of 17:20, 18 March 2025
Edmonton Protocol is a medical procedure that involves the transplantation of islet cells into a patient suffering from Type 1 diabetes. This procedure was developed at the University of Alberta, in Edmonton, Canada, hence the name.
History[edit]
The Edmonton Protocol was first developed and implemented in 1999 by a team of researchers led by Dr. James Shapiro. The team's groundbreaking work was published in the New England Journal of Medicine and has since been recognized as a significant advancement in the treatment of Type 1 diabetes.
Procedure[edit]
The Edmonton Protocol involves the transplantation of islet cells from a donor pancreas into the liver of a patient with Type 1 diabetes. The islet cells are infused into the patient's portal vein, where they lodge in the liver and begin to produce insulin.
Eligibility[edit]
Not all patients with Type 1 diabetes are eligible for the Edmonton Protocol. Candidates must have severe hypoglycemia unawareness and must have experienced at least one life-threatening hypoglycemic episode. They must also have poor blood glucose control despite optimal medical management.
Outcomes[edit]
While the Edmonton Protocol has shown promise, it is not a cure for Type 1 diabetes. Most patients still require some insulin therapy after the procedure. However, many patients experience a significant reduction in their insulin requirements and an improvement in their blood glucose control.
Limitations and Risks[edit]
The Edmonton Protocol is not without its limitations and risks. These include the limited availability of donor pancreases, the need for lifelong immunosuppressive therapy to prevent rejection of the transplanted islet cells, and the potential for complications related to the procedure itself.
Future Research[edit]
Research is ongoing to improve the outcomes of the Edmonton Protocol and to overcome its limitations. This includes research into alternative sources of islet cells, such as stem cells, and methods to reduce the need for immunosuppressive therapy.
